论文部分内容阅读
目的探讨诺舒阻抗子宫内膜切除系统(NovaSure)治疗月经过多的疗效及并发症。方法回顾性分析2012年2月至2014年12月行诺舒阻抗子宫内膜切除术治疗月经过多患者151例的临床资料及术后随访情况。结果 151例患者平均年龄(43.62±6.16)岁,84.77%(128/151)的患者合并贫血,20.53%(31/151)的患者合并严重内科疾病。平均宫腔深度(8.83±1.80)cm;平均手术时间(89.78±21.14)s,术中出血量均小于10ml;术后平均住院时间为(48.00±6.50)h,术后疼痛发生率为20.53%(31/151),阴道排液率为81.46%(123/151);术后随访3~37个月,平均随访(20.44±8.17)个月,有效率为94.04%(142/151),闭经率为53.64%(81/151),子宫切除率为2.65%(4/151)。结论 NovaSure治疗月经过多近期安全有效,但更远期效果仍需深入研究。
Objective To investigate the curative effect and complications of Novus impedance endometrial ablation system (NovaSure) in treating menorrhagia. Methods The clinical data and postoperative follow-up of 151 patients with menorrhagia treated with norgehv resistance endometrial ablation from February 2012 to December 2014 were retrospectively analyzed. Results 151 patients (43.62 ± 6.16) years of age, 84.77% (128/151) of patients with anemia, 20.53% (31/151) of patients with severe medical diseases. The mean uterine cavity depth was (8.83 ± 1.80) cm. The average operation time was 89.78 ± 21.14 s, and the intraoperative blood loss was less than 10 ml. The average postoperative hospital stay was (48.00 ± 6.50) h. The postoperative pain rate was 20.53% (31/151) and vaginal drainage rate was 81.46% (123/151). The average follow-up time was 3 to 37 months (20.44 ± 8.17) months, the effective rate was 94.04% (142/151) The rate of hysterectomy was 53.64% (81/151), hysterectomy rate was 2.65% (4/151). Conclusions NovaSure is safe and effective in the treatment of menorrhagia, but the more long-term effect needs further study.